Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Abercrombie & Fitch Co. (ANF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Abercrombie & Fitch Co. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.69 (market cap $29.60B), while Abercrombie & Fitch Co. trades at $113.13 (market cap $5.24B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.6× Abercrombie & Fitch Co.'s market cap, and Abercrombie & Fitch Co. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ANF | |
|---|---|---|
Market Cap | $29.60B | $5.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $129.85 |
52-Week Low | $205.48 | $65.61 |
Enterprise Value | $27.56B | $5.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
ANF trades at $114.45, down 3.44% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The stock shows strong fundamentals with a P/E of 11.41, net income margin of 9.34%, and three consecutive quarterly EPS beats. Revenue grew to $4.95 billion in 2025, up from $4.3 billion in 2024, while operating cash flow reached $710.38 million. Recent news highlights institutional buying and an upcoming Q2 2026 earnings report on August 26, 2026.
Outlook is mixed: valuation metrics appear attractive, and earnings momentum supports upside, but overbought RSI levels and competitive retail headwinds pose risks. Analyst consensus is a $112.86 price target with 35.71% buy ratings, suggesting cautious optimism amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →
